Obesity evidence dossier
Mazdutide
A high-efficacy GLP-1/glucagon dual agonist with completed US Phase 2 data.
Total weight loss
14.0%
GLORY-1 · 6 mg weekly · week 48 · Includes treatment stops
Placebo-adjusted
14.3%
Difference from placebo in the same study when reported.
Study context
Once-weekly GLP-1 and glucagon receptor dual agonist/Adults with obesity or overweight in China, without diabetes/610 participants across the study/48-week endpoint
Baseline: See the source for enrollment criteria
Ranked result & calculation
GLORY-1 · 6 mg weekly · 48 weeks
Adults with obesity or overweight in China, without diabetes. 610 participants across the study (not this dose arm alone).
Includes treatment stops. Treatment-policy results estimate outcomes regardless of stopping treatment.
- Average weight loss
- 14.01%
- Placebo group
- 0.3% gain
- Beyond placebo
- 14.31 percentage points (arm subtraction)
- 95% confidence interval, total loss
- 12.66–15.36%
- Stopped due to adverse events
- 0.5% treatment / 1% placebo
Week 48 secondary endpoint. Placebo gained 0.30%; a different 16 mg Phase 2 result is not substituted for this Phase 3 policy estimate.
Score: 70% × 57.6 total-loss points + 30% × 69.0 beyond-placebo points = 61/100, rounded. Conversion scales
GLORY-1, NEJM ↗Phase 3 · Journal article · Reviewed 2026-09-21
Evidence
Benchmark read
GLORY-1: Includes treatment stops. Week 48 secondary endpoint. Placebo gained 0.30%; a different 16 mg Phase 2 result is not substituted for this Phase 3 policy estimate.
Safety
Side effects and cautions
Discontinuation read
Stopped because of adverse events: 0.5% on treatment vs 1% on placebo.
Common side effects
Gastrointestinal adverse events were most common and mostly mild-to-moderate; treatment discontinuation due to adverse events was highest at 16 mg (20%), primarily from gastrointestinal disorders.
Main cautions
Investigational in the US; dose escalation and gastrointestinal tolerability are material considerations.
Upcoming catalyst
What to watch next
Further development decisions and additional clinical data following the completed US Phase 2 study.
Linked clinical trials
Trials in the saddl3 obesity snapshot
Non-diabetic obesity studies are prioritized; diabetes and healthy-volunteer studies remain visible and labeled.
NCT06164873
Phase 3
A Study of IBI362 9 mg in Chinese Adults With Obesity
Innovent Biologics (Suzhou) Co. Ltd.
Non-diabetic obesity
Aug 27, 2024
NCT07255209
Phase 3
A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
Innovent Biologics (Suzhou) Co. Ltd.
Non-diabetic obesity
Jan 8, 2026
NCT06884293
Phase 3
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
Innovent Biologics (Suzhou) Co. Ltd.
Non-diabetic obesity
May 14, 2025
NCT07469800
Phase 3
Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity
Innovent Biologics (Suzhou) Co. Ltd.
Non-diabetic obesity
Mar 13, 2026
NCT05607680
Phase 3
A Study of IBI362 in Participants With Obesity or Overweight
Innovent Biologics (Suzhou) Co. Ltd.
Non-diabetic obesity
Nov 12, 2024
NCT07000955
Phase 2
Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity
Innovent Biologics (Suzhou) Co. Ltd.
Non-diabetic obesity
Dec 15, 2025
NCT06143956
Phase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Eli Lilly and Company
Non-diabetic obesity
Mar 24, 2026
NCT06862908
Phase 2
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
Innovent Biologics (Suzhou) Co. Ltd.
Non-diabetic obesity
Jul 11, 2025
NCT04904913
Phase 2
A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects
Innovent Biologics (Suzhou) Co. Ltd.
Non-diabetic obesity
Nov 17, 2025
NCT06124807
Phase 2
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight
Eli Lilly and Company
Non-diabetic obesity
Jul 20, 2025
NCT04440345
Phase 2
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects
Innovent Biologics (Suzhou) Co. Ltd.
Non-diabetic obesity
Nov 28, 2023
NCT06536023
Phase 1
This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity
Innovent Biologics (Suzhou) Co. Ltd.
Non-diabetic obesity
Sep 12, 2025